NVCT
Nuvectis Pharma, Inc.7.69
+0.04+0.52%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
196.98MP/E (TTM)
-Basic EPS (TTM)
-1.37Dividend Yield
0%Recent Filings
10-K
FY2025 results
Nuvectis Pharma posted FY2025 net loss of $26.4M, up from $19.0M in FY2024, driven by R&D ramp to $18.2M (vs $12.9M) on NXP900 Phase 1a completion—90% SRC inhibition at 150mg+ doses with no DLTs—and Phase 1b launch, while ceasing NXP800 post-Phase 1b. Q4 momentum shone in DDI study confirming weak CYP3A inhibition and combo initiations with EGFR/ALK inhibitors. Cash swelled to $31.6M via $29M raises, funding ops into 2026+. No revenue; 13 employees. Clinical trial delays threaten progress.
8-K
2025 loss widens; cash extends runway
Nuvectis Pharma reported 2025 net loss of $26.4 million, up from $19.0 million in 2024, driven by higher R&D expenses of $18.2 million amid NXP900 Phase 1b progress in oncology targets. Cash climbed to $31.6 million from $18.5 million via February offering. Cash funds operations into late 2027. Multiple readouts loom in 2026.
8-K
NXP900 Phase 1b launches
Nuvectis Pharma kicked off its NXP900 Phase 1b program on November 4, 2025, with single-agent dosing underway in advanced cancer patients and combinations slated by year-end, building on completed Phase 1a and drug interaction studies showing strong pharmacodynamic responses. Q3 net loss widened to $7.5M from $4.2M year-over-year, driven by $2.0M NXP900 milestone and clinical costs, yet cash swelled to $35.4M. Runway lasts into 3Q-2027.
10-Q
Q3 FY2025 results
Nuvectis Pharma posted Q3 operating loss of $7.8M, up 79% y/y from $4.4M (derived), driven by $2.0M NXP900 license milestone and higher clinical expenses, while net loss hit $7.5M after $0.3M finance income. Cash swelled to $35.4M on $28.9M equity raises including February's $14.0M public offering and ATM sales. No revenue yet; R&D burn reflects Phase 1b NXP900 progress after halting NXP800 ovarian work. Cash funds operations 12+ months. Clinical trials remain unpredictable.
8-K
Appoints Sanchez to board
Nuvectis Pharma appointed biotech veteran Juan Sanchez, MD, to its board on September 22, 2025, effective until the 2026 annual meeting. Dr. Sanchez brings 30+ years blending medicine, Wall Street research, and exec roles at Intra-Cellular Therapies, sold to J&J for $14.6 billion. He joins as NXP900's Phase 1b kicks off. Board bolsters strategic depth.
CNTA
Centessa Pharmaceuticals plc
25.72-0.43
NBTX
Nanobiotix S.A.
22.32+0.18
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
NUVB
Nuvation Bio Inc.
8.66+0.15
NUVL
Nuvalent, Inc.
102.63-2.34
NVAX
Novavax, Inc.
6.54-0.04
PMVP
PMV Pharmaceuticals, Inc.
1.18-0.02
RNXT
RenovoRx, Inc.
0.84-0.10
VIRX
Viracta Therapeutics, Inc.
0.01+0.00
ZNTL
Zentalis Pharmaceuticals, Inc.
1.38-0.02